Interferon responsiveness does not change in treatment-experienced hepatitis c subjects: Implications for drug development and clinical decisions

Clinical Infectious Diseases

Volumn 55, Issue 5, 2012, Pages 639-644

  Liu, Jiang ^a   Florian, Jeffry ^a   Birnkrant, Debra ^b   Murray, Jeffrey ^b   Jadhav, Pravin R ^a  

^a Division of Pharmacometrics   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELAPREVIR; VIRUS RNA;

ANTIVIRAL THERAPY; ARTICLE; CLINICAL DECISION MAKING; CONTROLLED STUDY; EVIDENCE BASED MEDICINE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RESEARCH; PRIORITY JOURNAL; RELAPSE; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; ODDS RATIO; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84864955275     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis510     Document Type: Article

References (31)

1. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54:1433-44.
2. Guidance for industry chronic hepatitis C virus infection: developing direct-acting antiviral agents for treatment. Food and Drug Administration, Center for Drug Evaluation and Research. Available at: http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/UCM225333. pdf. Accessed 4 September 2010.
3. VanThiel DH, Friedlander L, Molloy PJ, et al. Retreatment of hepatitis C interferon non-responders with larger doses of interferon with and without phlebotomy. Hepato-Gastroenterology 1996; 43:1557-61.
4. Herrine SK, Brown RS, Bernstein DE, Ondovik MS, Lentz E, Te H. Peginterferon alpha-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha-2b plus ribavirin: a pilot study of efficacy and safety. Dig Dis Sci 2005; 50:719-26.
5. Taliani G, Gemignani G, Ferrari C, et al. Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. Gastroenterology 2006; 130:1098-106.
6. Zeuzem S. Difficult-to-treat patients with chronic hepatitis C. Praxis (Bern 1994) 2006; 95:1459-64.
7. Gerner P, Hilbich J, Wenzl TG, et al. Re-treatment of children with chronic hepatitis C who did not respond to interferon-alpha treatment. J Pediatr Gastroenterol Nutr 2010; 51:187-90.
8. Sherman M, Yoshida EM, Deschenes M, et al. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Gut 2006; 55:1631-8.
9. Jacobson IM, Gonzalez SA, Ahmed F, et al. A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. Am J Gastroenterol 2005; 100:2453-62.
10. Lindsay KL, Morishima C, Wright EC, et al. Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C. Clin Gastroenterol Hepatol 2008; 6:234-41.
11. Poynard T, Colombo M, Bruix J, et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ ribavirin therapy. Gastroenterology 2009; 136:1618-28. e2.
12. Zeuzem S, Sulkowski M, Lawitz E, et al. Albinterferon Alfa-2b Was Not Inferior to Pegylated Interferon-alpha in a Randomized Trial of Patients With Chronic Hepatitis C Virus Genotype 1. Gastroenterology 2010; 139:1257-66.
13. McHutchison J, Lawitz E, Shiffman M, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. New Engl J Med 2009; 361:580-93.
14. McHutchison J, Everson G, Gordon S, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. New Engl J Med 2009; 361:1827-38.
15. Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. New Engl J Med 2009; 360:1839-50.
16. Jacobson I, McHutchison J, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. New Engl J Med 2011; 364:2405-16.
17. Poordad F, McCone J, Bacon B, et al. Boceprevir for untreated chronic HCV genotype 1 infection. New Engl J Med 2011; 364:1195-206.
18. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364:2417-28.
19. Bacon B, Gordon S, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. New Engl J Med 2011; 364:1207-17.
20. Jadhav PR, Neal L, Florian J, et al. Antiviral Information Management System (AIMS): a prototype for operational innovation in drug development. J Clin Pharmacol 2010; 50 (9 suppl):50S-5.
21. Berg T, Sarrazin C, Herrmann E, et al. Prediction of treatment outcome in patients with chronic hepatitis C: Significance of baseline parameters and viral dynamics during therapy. Hepatology 2003; 37:600-9.
22. Barcena R, Moreno A, del Campo S, et al. The magnitude of week 4 HCV RNA decay on pegylated interferon/ribavirin accurately predicts virological failure in patients with genotype 1. Antivir Ther 2007; 12:401-6.
23. Martinot-Peignoux M, Maylin S, Moucari R, et al. Virological response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirin. Antivir Ther 2009; 14:501-11.
24. Toyoda H, Kumada T, Kiriyama S, et al. High ability to predict the treatment outcome of peginterferon and ribavirin combination therapy based on the reduction in HCV RNA levels at 4 weeks after starting therapy and amino acid substitutions in the hepatitis C virus in patients infected with HCV genotype 1b. J Gastroenterol 2011; 46:501-9.
25. Zeuzem S. Overview on Clinical Trials with Protease Inhibitors. In: 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy and 6th International Workshop on Hepatitis C Resistance and New Compounds. Boston. Available at: http://regist2. virologyeducation. com/2011/6HEPC/docs/JS-01- Zeuzem.pdf. Accessed 22 June 2011.
26. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399-401.
27. Hsu CS, Hsu SJ, Chen HC, et al. Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. Proc Natl Acad Sci USA 2011; 108:3719-24.
28. Shiffman ML, Morishima C, Dienstag JL, et al. Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial. Gastroenterology 2009; 137:1986-94.
29. Lee WM, Dienstag JL, Lindsay KL, et al. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 2004; 25:472-92.
30. Liu J, Jadhav PR, Amur S, et al. Response Guided Telaprevir Therapy in Prior Relapsers? The Role of Bridging Data from Treatment-Naive and Experienced Subjects. In: The 62nd Annual Meeting of the American Association for the Study of Liver Diseases. San Francisco, CA, 2011.
31. Florian J, Jadhav PR, Amur S, et al. Boceprevir Dosing for Late Responders and Null Responders: The Role of Bridging Data between Treatment-Naive and Experienced Subjects. In: The 62nd Annual Meeting of the American Association for the Study of Liver Diseases. San Francisco, CA, 2011.